Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates

Tim A. Weaver, Ali H. Charafeddine, Avinash Agarwal, Alexandra P. Turner, Maria Russell, Frank V. Leopardi, Robert L. Kampen, Linda Stempora, Mingqing Song, Christian P. Larsen, Allan D. Kirk

Research output: Contribution to journalArticlepeer-review

161 Scopus citations


Memory T cells promote allograft rejection particularly in co-stimulation blockade-based immunosuppressive regimens. Here we show that the CD2-specific fusion protein alefacept (lymphocyte function-associated antigen-3-Ig; LFA -3-Ig) selectively eliminates memory T cells and, when combined with a co-stimulation blockade-based regimen using cytotoxic T lymphocyte antigen-4 (CTLA-4)-Ig, a CD80- and CD86-specific fusion protein, prevents renal allograft rejection and alloantibody formation in nonhuman primates. These results support the immediate translation of a regimen for the prevention of allograft rejection without the use of calcineurin inhibitors, steroids or pan-T cell depletion.

Original languageEnglish
Pages (from-to)746-749
Number of pages4
JournalNature Medicine
Issue number7
StatePublished - Jul 2009
Externally publishedYes


Dive into the research topics of 'Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates'. Together they form a unique fingerprint.

Cite this